These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3393236)

  • 1. Enhancement of muscle blood cell flux and pO2 by cromakalim (BRL 34915) and other compounds enhancing membrane K+ conductance, but not by Ca2+ antagonists or hydralazine, in an animal model of occlusive arterial disease.
    Angerbach D; Nicholson CD
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Mar; 337(3):341-6. PubMed ID: 3393236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil.
    Yanagisawa T; Teshigawara T; Taira N
    Br J Pharmacol; 1990 Sep; 101(1):157-65. PubMed ID: 2149290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.
    McPherson GA; Stork AP
    Br J Pharmacol; 1992 Jan; 105(1):51-8. PubMed ID: 1534504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.
    Yanagisawa T; Hashimoto H; Taira N
    Br J Pharmacol; 1988 Oct; 95(2):393-8. PubMed ID: 2852521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cromakalim does not protect against skeletal muscle fatigue in an anaesthetized rat model of acute hindlimb ischaemia.
    Trezise DJ; Drew GM; Roach AG; Watts IS; Weston AH
    Eur J Pharmacol; 1993 Nov; 250(1):109-16. PubMed ID: 8119308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that pinacidil may promote the opening of ATP-sensitive K+ channels yet inhibit the opening of Ca2(+)-activated K+ channels in K(+)-contracted canine mesenteric artery.
    Masuzawa K; Matsuda T; Asano M
    Br J Pharmacol; 1990 May; 100(1):143-9. PubMed ID: 2115387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of intracellular calcium by potassium channel openers in vascular muscle.
    Erne P; Hermsmeyer K
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Dec; 344(6):706-15. PubMed ID: 1775202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of action of the novel antihypertensive agent, BRL 34915, as a potassium channel activator. Comparison with nicorandil.
    Coldwell MC; Howlett DR
    Biochem Pharmacol; 1987 Nov; 36(21):3663-9. PubMed ID: 2445348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma.
    Nagai H; Kitagaki K; Goto S; Suda H; Koda A
    Jpn J Pharmacol; 1991 May; 56(1):13-21. PubMed ID: 1831870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of K+ conductance of heart cell membrane by BRL 34915.
    Osterrieder W
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jan; 337(1):93-7. PubMed ID: 3368016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of responses to cromakalim and pinacidil in smooth and cardiac muscle by use of selective antagonists.
    McPherson GA; Angus JA
    Br J Pharmacol; 1990 Jun; 100(2):201-6. PubMed ID: 2116201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pinacidil, cromakalim, and nicorandil on potassium currents of rat basilar artery smooth muscle.
    Zhang H; Stockbridge N; Weir B
    Adv Exp Med Biol; 1991; 304():531-41. PubMed ID: 1839488
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+.
    Wilson C; Cooper SM
    Br J Pharmacol; 1989 Dec; 98(4):1303-11. PubMed ID: 2575415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.
    Atwal KS
    J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S12-7. PubMed ID: 7898103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of K+ channel agonists cromakalim and pinacidil on rat basilar artery smooth muscle cells are mediated by Ca(++)-activated K+ channels.
    Stockbridge N; Zhang H; Weir B
    Biochem Biophys Res Commun; 1991 Nov; 181(1):172-8. PubMed ID: 1958186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities in the mechanism of action of two new vasodilator drugs: pinacidil and BRL 34915.
    Cook NS; Quast U; Hof RP; Baumlin Y; Pally C
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):90-9. PubMed ID: 2450263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential vasorelaxant effects of K(+)-channel openers and Ca(2+)-channel blockers on canine isolated arteries.
    Iwamoto T; Nishimura N; Morita T; Sukamoto T
    J Pharm Pharmacol; 1993 Apr; 45(4):292-7. PubMed ID: 8098370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil.
    Wilson C; Coldwell MC; Howlett DR; Cooper SM; Hamilton TC
    Eur J Pharmacol; 1988 Aug; 152(3):331-9. PubMed ID: 2851450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.